Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma

Omid Hamid^*, Igor Puzanov, Reinhard Dummer, Jacob Schachter, Adil Daud, Dirk Schadendorf, Christian Blank, Lee D. Cranmer, Caroline Robert, Anna C. Pavlick, Rene Gonzalez, F. Stephen Hodi, Paolo A. Ascierto, April K.S. Salama, Kim A. Margolin, Tara C. Gangadhar, Ziwen Wei, Scot Ebbinghaus, Nageatte Ibrahim, Antoni Ribas

^*Corresponding author for this work

Angeles Clinic and Research Institute
Vanderbilt University
University of Zurich
Sheba Medical Center at Tel Hashomer
University of California at San Francisco
University of Duisburg-Essen
Netherlands Cancer Institute
University of Arizona
Université Paris-Saclay
New York University
University of Colorado Anschutz Medical Campus
Dana-Farber Cancer Institute
IRCCS Istituto nazionale tumori Fondazione Giovanni Pascale - Napoli
Duke University
City of Hope Duarte
University of Pennsylvania
Merck
University of California at Los Angeles

Research output: Contribution to journal › Article › peer-review

159 Scopus citations

Sort by
Weight
Alphabetically

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma

Fingerprint

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science